The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
High pretreatment neutrophil-to-lymphocyte ratio (NLR) and its reactive increase as better predictors of poor clinical outcomes compared to tumor mutation burden (TMB) in solid tumor patients treated with immune checkpoint inhibitors (ICI).
 
Vaia Florou
No Relationships to Disclose
 
Wungki Park
No Relationships to Disclose
 
Alfredo Enrique Torres
No Relationships to Disclose
 
Sandra Algaze
No Relationships to Disclose
 
Diana Saravia
No Relationships to Disclose
 
Breelyn A. Wilky
Consulting or Advisory Role - Janssen Oncology; Lilly; Novartis
Research Funding - Agenus; ArQule; Daiichi Sankyo; Merck Sharp & Dohme; Novartis
Travel, Accommodations, Expenses - Advenchen Laboratories; Lilly; Novartis
 
Jaime R. Merchan
Consulting or Advisory Role - Exelixis
Research Funding - Astellas Pharma; Eisai; Genentech; Halozyme; Lilly; Novartis; Peloton Therapeutics; Rexahn Pharmaceuticals; Viralytics; Vyriad
 
Peter Joel Hosein
Consulting or Advisory Role - Angiodynamics; Angiodynamics; Celgene; Medtronic
 
Albert Craig Lockhart
No Relationships to Disclose
 
Gilberto Lopes
Research Funding - AstraZeneca (Inst); EMD Serono (Inst); Merck Sharp & Dohme (Inst)